PER-005-20已完成未知
A PHASE 1/2 STUDY OF ARQ 092 (MIRANSERTIB) IN SUBJECTS WITH PIK3CA-RELATED OVERGROWTH SPECTRUM AND PROTEUS SYNDROME
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2020年7月17日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Signed informed consent, and when applicable, signed assent
- •2.Cohort 1 (PROS) specific criteria
- •Male or female subjects ≥ 2 years and ≤30 years of age with BSA of ≥ 0.33 m2
- •Have clinical diagnosis of PROS per Diagnostic Criteria for PROS (see Appendix 1) and documented somatic PIK3CA variant
- •Have at least one lesion that can be measured by study- standardized volumetric MRI (eligibility to be confirmed by blinded independent central imaging review
- •3.Cohort 2 (PS) specific criteria
- •Male or female subjects ≥ 2 years and ≤18 years of age with BSA of ≥ 0.33 m2
- •Have clinical diagnosis of PS per Diagnostic Criteria for PS (see Appendix 1) and documented somatic AKT1 variant
- •Have at least one plantar CCTN and pre-CCTN lesion that can be measured by standardized photography. The CCTN is defined as a nevus with at least two gyri and three sulci and should affect between 10% and 70% of the total surface area of the foot (eligibility to be confirmed by the study central imaging)
- •4.Cohort 3 specific criteria
- •Male or female subjects ≥2 years old with BSA of ≥ 0.33 m2 and who fail to meet the eligibility criteria for Cohorts 1 or 2
- •5.Cohort 4 (PROS or PS) specific criteria
- •Subjects previously treated with ARQ 092 or currently receiving ARQ 092 under Compassionate Use/Expanded Access
- •All Cohorts:
- •6.Archival or fresh overgrowth tissue sample available to be shipped to Sponsor or designee
- •Except for Cohort 4, clinically progressive or worsening disease defined as an increase in number or size of the overgrowth lesion(s) in the last 6 months as assessed by the Investigator
- •8.Adequate organ function as indicated by the following laboratory values:
- •Hematological
- •a.Hemoglobin (Hgb) depending on age:
- •2-5 years male and female: ≥ 10.0 g/dL 6-9 years male and female: ≥ 11.5 g/dL 10-17 years female: ≥ 11.0 g/dL
- •10-17 years male: ≥ 11.5 g/dL
- •≥18 years male and female: ≥ 10.0 g/dL
- •b.Glycated hemoglobin (HbA1c): ≤ 8% (≤ 64 mmol/mol)
- •c.Absolute neutrophil count (ANC): ≥ 1.5 x 109/L
- •d.Platelet count ≥ 150 x 109/L Hepatic
- •a.Total bilirubin ≤ 1.5 x upper limit of normal (ULN)/L
- •b.Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN
- •a. Serum creatinine depending on age:
- •2-5 years male and female: maximum 0.80 mg/dL 6-10 years male and female: maximum 1.0 mg/dL 11-15 years male and female: maximum 1.2 mg/dL
- •> 15 years male and female: maximum 1.5 mg/dL
- •b. Estimated Glomerular Filtration Rate (eGFR):
- •≥ 60 mL/min/1.73 m2 Metabolic (lipids)
- •a.Cholesterol: ≤ 400 mg/dL (≤ 10.34 mmol/L)
- •b.Triglyceride: ≤ 500 mg/dL (≤ 5.7 mmol/L)
- •9.Male or female subjects of child-producing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after the last dose of ARQ 092
- •10.Ability to complete the study questionnaires by the subject or his/her caregiver
排除标准
- •1.History of Type 1 diabetes mellitus or Type 2 uncontrolled diabetes mellitus requiring regular medication (other than metformin or other oral hypoglycemic agents) or fasting glucose ≥ 160 mg/dL (if > 12 years old) and ≥ 180 mg/dL (if ≤ 12 years old) at the screening visit
- •2.History of significant cardiac disorders:
- •Myocardial infarction (MI) or congestive heart failure defined as Class II-IV per the New York Heart Association (NYHA) classification within 6 months of the first dose of ARQ 092 (MI occurring > 6 months of the first dose of ARQ 092 will be permitted)
- •Grade 2 (per current version of National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE]) or worse conduction defect (e.g., right or left bundle branch block)
- •Major surgery or locoregional therapy within four weeks of the first dose of ARQ 092
- •3.Any experimental systemic therapy for the purposes of treating PROS or PS (e.g., sirolimus, everolimus, high dose steroids) within two weeks of the first dose of ARQ 092
- •4.Intolerance of or severe toxicity attributed to AKT inhibitors (e.g., ARQ 092, uprosertib, afuresertib, ipatasertib)
- •5.Concurrent severe uncontrolled illness not related to PROS or PS, e.g.,
- •Ongoing or active infection
- •Known human immunodeficiency virus (HIV) infection
- •Malabsorption syndrome
- •Psychiatric illness/substance abuse/social situation that would limit compliance with study requirements
- •6.Pregnant or breastfeeding
- •7.Inability to comply with study evaluations or to follow drug administration guidelines
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS)PIK3CA-related overgrowth spectrum (PROS) and Proteus syndrome (PS).MedDRA version: 20.0Level: LLTClassification code 10018058Term: Gene genetic abnormalitySystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10069758Term: Somatic mutationSystem Organ Class: 100000004867EUCTR2016-000558-37-ESArQule, Inc.65
进行中（未招募）
1 期
A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS)EUCTR2016-000558-37-GBArQule, Inc.65
进行中（未招募）
1 期
A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS)PIK3CA-related overgrowth spectrum (PROS) and Proteus syndrome (PS).MedDRA version: 20.0 Level: LLT Classification code 10018058 Term: Gene genetic abnormality System Organ Class: 100000004850MedDRA version: 22.0 Level: LLT Classification code 10069758 Term: Somatic mutation System Organ Class: 100000004867EUCTR2016-000558-37-FRArQule, Inc.65
进行中（未招募）
1 期
A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS)EUCTR2016-000558-37-DEMerck Sharp & Dohme Corp65
进行中（未招募）
1 期
Study of patients with an increase in the size of certain parts of their body and circulatory abnormalities.subjects (at least 6 years) suffering from diseases overgrowth and vascular anomalies with genetic alterations of the PI3K / AKT pathway.MedDRA version: 20.0 Level: SOC Classification code 10010331 Term: Congenital, familial and genetic disorders System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-000558-37-ITArQule, Inc.16